

ISSUER INFORMATION AND DISCLOSURE STATEMENT  
PURSUANT TO  
Rule 15c2-11

## QUARTERLY REPORT

June 30, 2017



## ECO-PETROLEUM SOLUTIONS, INC.

120 W. Pomona Avenue  
Monrovia, CA 91016  
(626) 538-4779

Federal ID No.: 30-0808561

CUSIP No.: 863556 10 6

### ISSUER'S EQUITY SECURITIES

#### Capital Stock

600,000,000 Shares of Common Stock authorized, par value \$0.0001 per share  
121,053,470 common shares issued and outstanding as of June 30, 2017  
121,053,470 common shares issued and outstanding as of September 12, 2017

## INFORMATION AND DISCLOSURE STATEMENT

All information in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of Rule 15c2-11 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The enumerated items and captions contained herein correspond to the format as set forth in that rule.

### Forward-looking Statements

This Information and Disclosure Statement contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements represent the Company's expectations or beliefs concerning future events. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions are intended to identify forward-looking statements. The Company cautions that these statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements, including without limitations, the factors described in this Information and Disclosure Statement.

Investors are cautioned not to place undue reliance on such forward-looking statements because they speak only of the Company's views as of the statement dates. Although the Company has attempted to list the important factors that presently affect the Company's business and operating results, the Company further cautions investors that other factors may in the future prove to be important in affecting the Company's results of operations. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

### PART A: GENERAL COMPANY INFORMATION

#### Item I. The exact name of the issuer and its predecessor (if any) and the dates of the name changes.

The exact name of the issuer is: Eco-Petroleum Solutions, Inc.

#### Formerly

#### Date changed

Structural Enhancement Technologies Corp.	November 16, 2012
Extreme Mobile Coatings Worldwide Corp.	May 19, 2010
Extreme Mobile Coatings Corp., Ltd.	March 2, 2009
Falcon Media Services, Ltd.	November 12, 2008
T&T Homes Limited	November 25, 2004

#### Item II. The address of the issuer's principal executive offices.

The address of the issuer's principal executive offices is:

120 W. Pomona Avenue  
Monrovia, CA 91016  
(626) 538-4779

#### Item III. The state and date of the issuer's incorporation or organization.

State of Incorporation:	United Kingdom (currently Delaware)
Date Incorporated:	July 28, 2004

Item IV. The exact title of securities outstanding.

- 1) Common Stock, \$0.0001 par value per share  
Cusip Number – 863556 10 6  
Trading Symbol – ECPO.PK
  - A. Each holder of Common Stock is entitled to one vote for each share held of record on each matter submitted to vote to stockholders, including election of directors. Stockholders do not have any right to cumulate votes on the election of directors. Each holder of Common Stock is entitled to share ratably in distributions to stockholders and to receive ratably such dividends as may be declared by the Board of Directors out of funds legally available therefore. In the event of the Company's liquidation, dissolution or winding up, the holders of Common Stock will be entitled to receive, after payment of all of the Company's debts and liabilities and of all sums to which holders of any outstanding preferred stock, if any, may be entitled, the distribution of any of the Company's remaining assets. Holders of the Company's Common Stock have no conversion, exchange, sinking fund, redemption or appraisal rights (other than such as may be determined by the Board of Directors in its sole discretion) and have no preemptive rights to subscribe for any of its securities. There are no provisions in the Company's Articles of Incorporation or By-Laws that would delay, defer, or prevent a change of control of the Company.
  - B. As of June 20, 2017, the Company was authorized to issue 600,000,000 shares of Common Stock. As of June 30, 2017, the Company had 121,053,470 shares of Common Stock issued and outstanding.
- 2) Series A Preferred Stock, par value of \$0.0001 per share  
Cusip Number – N/A  
Trading Symbol – N/A
  - A. The Record Holders of the Series A Preferred Shares shall have the right to vote on any matter with holders of common stock voting together as one (1) class. The Record Holders of the Series A Preferred Shares shall have that number of votes (identical in every other respect to the voting rights of the holders of other Series of voting preferred shares and the holders of common stock entitled to vote at any Regular or Special Meeting of the Shareholders) equal to that number of common shares which is not less than 51% of the vote required to approve any action, which Delaware law provides may or must be approved by vote or consent of the holders of other series of voting preferred shares and the holders of common shares or the holders of other securities entitled to vote, if any. **For purposes of determining the number of votes, each one (1) share of the Series A Preferred shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding common stock eligible to vote at the time of the respective vote (the "Numerator"), divided by (y) 0.49, minus (z) the Numerator.**
  - B. As of June 30, 2017, the Company was authorized to issue 60,000,000 shares of Series A Preferred Stock. As of June 30, 2017, the Company had 60,000,000 shares of Series A Preferred Stock issued and outstanding. As of September 12, 2017, the Company had 60,000,000 shares of Series A Preferred Stock issued and outstanding
- 3) Series B Preferred Stock, par value of \$0.0001 per share  
Cusip Number – N/A  
Trading Symbol – N/A
  - A.
    - i. 100,000,000 shares of Series B Preferred, par value of \$0.0001, to be issued in exchange for the currently issued and outstanding 200,000,000 shares of Immunotech Laboratories, Inc, Series B Preferred Stock currently issued and outstanding on a one (1) newly issued Series B Preferred Stock, par value \$0.0001 for each two (2) of the Immunotech Laboratories, Inc. Series B Preferred Stock;
    - ii. 288,982,484 shares of Series B Preferred, par value of \$0.0001, to be issued in exchange for the currently issued and outstanding 577,964,967 shares of Immunotech Laboratories, Inc, common stock on a one (1) newly issued Series B Preferred Stock, par value \$0.0001 for each two (2) of the Immunotech Laboratories, Inc. common stock, except that no common stock shareholder shall receive any partial share, and if such partial share would be issued, the share shall be rounded up to the nearest whole share, and this number of shares issued pursuant to this subsection shall be adjusted accordingly.
  - B. As of June 30, 2017, the Company was authorized to issue 465,000,000 shares of Series B Preferred Stock.

As of June 30, 2017, the Company had 100,000 shares of Series B Preferred Stock issued and outstanding. As of September 12, 2017, the Company had 100,000,000 shares of Series B Preferred Stock issued and outstanding.

The name and address of the transfer agent:

The Issuer's Stock Transfer Agent is:

Nevada Agency and Transfer Company  
50 West Liberty Street, Suite 880  
Reno, Nevada 89501  
Tel. No. (775) 322-0626  
Facsimile No. (775) 322-5623

The transfer agent is registered under the Exchange Act and is regulated by the Securities and Exchange Commission.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months

None

Within the past year please list any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization:

On March 9, 2017, the Company entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock. The 60,000,000 million Immunotech Series A preferred shares are being exchanged one for one for the Newly Created ECPO Preferred Series A with the exact same voting preference as the Immunotech Series A preferred. Immunotech's 200 Million outstanding Series B Preferred are being exchanged two for one but do have a voting preference and shall be exchanged for 100 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Company will issue 287,482,484 series B preferred in exchange of 574,964,967 of common stock of Immunotech. This transaction is still in process. Currently the Company has acquired voting control and majority ownership of Immunotech Laboratories, Inc. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Upon conversion of the Newly Created ECPO series B the shareholders of IMMB participating in the Share Exchange Agreement will own 80% of the issued and outstanding of ECPO. No common stock of ECPO will be issued until the Newly Created Preferred Series B is Converted.

## Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such person or entities:

On January 28, 2015, the Company issued 18,000,000 shares of common stock for various activities and as a bonus for services performed on behalf of the Corporation to officers and directors and/or consultants of the Company, to the following:

Andrew B. Mazzone	4,000,000
James Zimble/Advanta Management Consulting	4,000,000
Jeffrey Gates	4,000,000
Robert Rosinski	3,000,000
Randy Wegner	3,000,000

On January 28, 2015, the Company issued 8,000,000 shares of common stock for the acquisition of Bottled Brands LLC, as follows:

Rodney Barrington	4,000,000
Paula Barrington	4,000,000

On February 3, 2015, the Company issued 28,000,000 shares of common stock for various activities and services to be performed on behalf of the Corporation to officers and directors and/or consultants of the Company, to the following:

Andrew B. Mazzone	4,000,000
James Zimble/Advanta Management Consulting	4,000,000
Jeffrey Gates	4,000,000
Robert Rosinski	4,000,000
Randy Wegner	4,000,000
Rodney Barrington	4,000,000
Paula Barrington	4,000,000

On February 5, 2015, the Company issued 24,000,000 shares of common stock for various activities and services to be performed on behalf of the Corporation to consultants of the Company, to the following:

Senior Management Solutions, Inc.	8,000,000
CKM Corporate, Inc.	8,000,000
Ernest B. Remo	8,000,000

On February 8, 2015, the Company issued 8,000,000 shares of common stock as inducement to forebear on debt owed to Cimarron Capital, Ltd.

On February 10, 2015, the Company issued a total of 10,000,000 shares to Mr. Mergenthaler in settlement of \$190,000 of the amount due him, reducing the total amount owed to from \$283,500 to the amount of \$93,000.

On March 9, 2017 the Company entered into a Share Exchange Agreement with shareholders of Immunotech Laboratories, Inc. at which time the Company issued 30,000,000 Eco-Petroleum Solutions, Inc. Series A Preferred to Harry Zhabilov. 6,000,000 shares of Series A Preferred to the Estate of Alie Chang, 10,000,000 shares of Series A Preferred to Zhabilov Trust and 4,000,000 shares of Series A to Dimitar Savov in a one for one exchange for each individuals Series A Preferred shares, respectively of Immunotech Laboratory, Inc.

On March 9, 2017 as a result of the Share Exchange Agreement the Company issued 60,000,000 Series B Preferred shares of Eco-Petroleum Solution, Inc. to Dimitar Savov and issued 40,000,000 Series B Preferred shares to Harry Zhabilov in a two for one exchange for each individuals Series B Immunotech Laboratories, Inc. Series B Preferred shares, respectively.

On June 21, 2017 the Company issued 9,414,312 common stock to Southridge Partners II LP for the conversion of

\$5,000 of debt and accrued interest acquired from Cimarron Capital Ltd.

With respect to all shares listed above, the shares were issued in reliance upon the exemptions from the registration requirements of Section 5 of the Securities Act of 1933, as amended (the “Act”), pursuant to Section 4(2) of the Act. The certificates evidencing the above-mentioned shares contain a legend (1) stating that the shares have not been registered under the Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Act.

Item V. Financial information for the issuer’s most recent fiscal period.

The unaudited financial statements of the issuer as of June 30, 2015 and 2016, and for the years then ended, and cumulative from inception are hereby incorporated by reference and can be found on [www.OTCmarkets.com](http://www.OTCmarkets.com).

Item VI. The nature of the issuer’s business.

A. Business Development

Eco-Petroleum Solutions, Inc. is a Delaware corporation in the development stage. The Corporation was initially incorporated, under the name of T and T Homes Limited on July 28, 2004, in the United Kingdom. On November 25, 2004, the name of the Corporation was amended to be Falcon Media Services, Ltd. On November 12, 2008, the Company changed its name to Extreme Mobile Coatings Corp., Ltd. On March 2, 2009, the Company changed its name to Extreme Mobile Coatings Worldwide Corp. On May 19, 2010, the Company changed its name to Structural Enhancement Technologies Corp. Lastly, on November 16, 2012, the Company amended its name to Eco-Petroleum Solutions, Inc. to indicate a change in its business plan to expand its operations by entering into the renewable energy sector to conduct the business of blending, bottling, and distributing private label motor oil, transmission fluid, and related products for the automotive aftermarket.

On July 21, 2017 the Company submitted a request for a name and symbol change as a result of merger to FINRA Corporate Actions to change the name of the Company from Eco-Petroleum Solutions, Inc. to Immunotech Laboratories, Inc. to indicate the Company’s entrance into the Drug Development Industry for Immunotherapies. The Company has received comments and responded and expects the process to be completed within the 90 day time frame.

B. Business of the Issuer

On March 9, 2017, the Company entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock. The 60,000,000 million Immunotech Series A preferred shares are being exchanged one for one for the Newly Created ECPO Preferred Series A with the exact same voting preference as the Immunotech Series A preferred. Immunotech’s 200 Million outstanding Series B Preferred are being exchanged two for one but do have a voting preference and shall be exchanged for 100 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Company will issue 287,482,484 series B preferred in exchange of 574,964,967 of common stock of Immunotech. This transaction is still in process. Currently the Company has acquired voting control and majority ownership of Immunotech Laboratories, Inc. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Upon conversion of the Newly Created ECPO series B the shareholders of IMMB participating in the Share Exchange Agreement will own 80% of the issued and outstanding of ECPO. No common stock of ECPO will be issued until the Newly Created Preferred Series B is Converted.

Immunotech Laboratories, Inc. is a drug development company and holder of an exclusive license to a US Patented Immunotherapy for the treatment of HIV/Aids and Hepatitis C. The Company is currently in the research and development stage of operations and has successfully completed phase three of clinical trials on its Immunotherapy Treatment for the HIV/Aids virus in Bulgaria. The Company’s 49% owned subsidiary IMMB BG has filed, in the

Fourth Qtr. of 2016, for the permit to allow sale of the treatment to Aids patients with the HIV/Aids virus in Bulgaria. The Company has begun manufacturing of the validation order which is required for issuance of the permit.

The Company's Standard Industrial Code (SIC) is 541711. The Company's Secondary SIC code is 541990.

The Company has never been a "shell company".

The Company's fiscal year end is December 31.

Immunotech Laboratories Inc. a Nevada Corporation incorporated on April 11, 2000, is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. The Company is dedicated to the commercialization of these License rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Immunotech Laboratories Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

ITV, produced by Immunotech Laboratories, Inc. is a brand new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelop protein "in vitro" was demonstrated.

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with new comers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching \$ 15 billion in year 2012, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost and eventual viral resistance.

In summation our product's differentiation is based on:

- 1- Minimal and minor side effects
- 2- Zero toxicity issues
- 3- Tremendous cost savings
- 4- Short and limited treatment cycle
- 5- Easier Compliance adherence
- 6- Zero risk of viral resistance and mutation

#### C. Employees

The Company, other than Officers and Directors, has no full time employees.

#### Item VII. The nature and extent of the issuer's facilities.

Immunotech Laboratories, Inc. operates out of a 1,655 sq. ft. facility located in Monrovia, CA in Hamby Industrial Park under a two year lease expiring on March 31, 2015. All lease payments are current under the lease. The President Harry Zhabilov is guarantor on the lease.

All leaseholds indicated are sufficient for the needs of the Issuer and its subsidiaries for the foreseeable future.

Item VIII. The name of the chief executive officer, members of the Board of Directors, as well as control persons.

A. Executive Officers, Directors, and Key Personnel

Members of the Board of Directors serve until the next annual meeting of stockholders and until their successors are elected and qualified. Officers are appointed by and serve at the discretion of the Board.

NAME

POSITION

Harry H. Zhabilov

President and Sole Director

B. Legal/Disciplinary History

1. During the past five (5) years, none of the Company's officers or directors has a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding.
2. During the past five (5) years none of the Company's officers or directors has the entry of an order, judgment, or decree by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities.
3. During the past five (5) years, none of the Company's officers or directors has a finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law.
4. During the past five (5) years, none of the Company's officers or directors has the entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

C. Disclosure of Family Relationships. None

D. Disclosure of Related Party Transactions.

E. Disclosure of Conflicts of Interest. None

Item IX. Beneficial Owners.

The following table sets forth information regarding beneficial ownership as of the date of this Annual Report by (i) each Named Executive Officer, (ii) each member of the Company's Board of Directors, (iii) each person deemed to be the beneficial owner of more than five percent (5%) of any class of the Company's common stock, and (iv) all of the Company's Executive Officers and Directors as a group. Unless otherwise indicated, each person named in the following table is assumed to have sole voting power and investment power with respect to all shares of the



Company's common stock listed as owned by such person. Unless otherwise noted, the address for each reporting person below is the Company's principal executive office address.

<u>Name and Position</u>	<u>Shares of Common Stock(1)</u>	<u>Percentage of Class (Common)</u>
Andrew B. Mazzone – Chairman and CEO (2)	9,000,000	8%
Harry H. Zhabilov (3)	-	-
Jeffrey Gates	15,000,012	13.4%
Directors and Officers as a group (1 people) (1)(4)	-	51%

(1) As of June 30, 2015, The Company had 121,053,470 shares of its common stock issued and outstanding.

(2) Mr. Mazzone passed away of February 21, 2017.

(3) A part of the March 9, 2017 Share Exchange Agreement between the Company and Immunotech Laboratories, Inc., Mr. Zhabilov was issued 30,000,000 shares Preferred Series A Stock which represents majority voting rights of over 51% of the total issued and outstanding shares of common stock at the time of voting. Mr. Zhabilov was also issued 40,000,000 shares of Series B Preferred Stock.

(4) As part of the March 9, 2017 Share Exchange Agreement between the Company and Immunotech Laboratories, Inc., Dimitar Savov was issued 4,000,000 shares Preferred Series A Stock. Mr. Savov was also issued 60,000,000 shares of Series B Preferred Stock.

(5) As part of the March 9, 2017 Share Exchange Agreement between the Company and Immunotech Laboratories, Inc., Zhabilov Trust was issued 10,000,000 shares Preferred Series A Stock.

(6) As part of the March 9, 2017 Share Exchange Agreement between the Company and Immunotech Laboratories, Inc., the Estate of Alie Chang was issued 6,000,000 shares Preferred Series A Stock.

Item X. The name of any outside providers that advise the issuer on matters relating to the operations, business development, and disclosure. The information should include the advisor(s) name, address, telephone, and email address.

1. Investment Banker;

None

2. Promoters; Placement Agents

None.

3. Counsel;

SEC Corporate Counsel:

Morgan E. Petitti, Esq.  
114 Barrington Town Square, Suite 159  
Aurora, Ohio 44202  
Telephone: 330.697.8548  
Fax: 330.748.4689  
E-Mail: [PetittiLaw@gmail.com](mailto:PetittiLaw@gmail.com)

4. Accountant or Auditor - The information should clearly describe if an outside accountant provides audit or review services, state the work done by the outside accountant, describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer's financial statements, etc.).

Accountant/Auditor

Our Accountant is:

Jona Barnes, E.A., Partner  
Mallett & Barnes Tax Service  
6136 Mission Gorge Road, Suite  
125 San Diego, CA 92120  
(619) 326-0840  
Fax (619) 326-0843

5. Public Relations Consultant(s)

None.

6. Investor Relations Consultant(s)

None.

[Balance of Page Intentionally Left Blank]

Item XI. Issuer's Certifications.

I, Harry H. Zhabilov, Director and Chief Executive Officer, certify that:

1. I have reviewed this Quarterly Report as of June 30, 2017, of Eco-Petroleum Solutions, Inc., a Delaware corporation; and,
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, and is not misleading with respect to the period covered by this disclosure statement; and,
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly represent in all material respects, the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this information and disclosure statement.

September 11, 2017

/s/ Harry H. Zhabilov  
Harry H. Zhabilov  
Chief Executive Officer, Chief Financial Officer and Sole Director

